GSNO Therapeutics

GSNO Therapeutics is a preclinical-stage biotech developing GSNOR inhibitors, with GTI-850 as its lead asset. The platform is based on increasing endogenous GSNO levels, a natural signaling molecule, to achieve therapeutic effects across 56 identified activities in 26 animal models, including ophthalmology, inflammatory bowel disease, and age-related conditions. The company is preparing for initial clinical trials in autoimmune conjunctivitis and dry eye, positioning itself as a potential developer of safer alternatives to steroids and JAK inhibitors.

Platform based on inhibiting S-nitrosoglutathione reductase (GSNOR) to elevate endogenous levels of S-nitrosoglutathione (GSNO), a key signaling molecule that regulates protein function via S-nitrosylation. This homeostatic modulation targets multiple disease drivers including inflammation, fibrosis, autoimmunity, and oxidative stress.

In ophthalmology, GTI-850 would compete with steroids, calcineurin inhibitors, and newer anti-inflammatories. In IBD, competition includes steroids, biologics (anti-TNF, etc.), and JAK inhibitors. The platform's uniqueness lies in its novel GSNO-based mechanism, but other companies may be exploring nitrosylation biology or developing GSNOR inhibitors, creating potential for future competition.